141
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Utility of Self-Administered Questionnaires for Identifying Individuals at Risk of COPD in Japan: The OCEAN (Okinawa COPD casE finding AssessmeNt) Study

, , , , , ORCID Icon, ORCID Icon, , , , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1771-1782 | Published online: 17 Jun 2021

References

  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD. 2021. Available from: https://goldcopd.org/gold-reports/. Accessed May 21, 2021.
  • Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442
  • Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X
  • World Health Organisation. The top 10 causes of death. 2020. Available from: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed May 21, 2021.
  • Landis SH, Muellerova H, Mannino DM, et al. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611. doi:10.2147/COPD.S61854
  • Igarashi A, Fukuchi Y, Hirata K, et al. COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2018;13:2629–2641. doi:10.2147/COPD.S167476
  • Ishii T, Nishimura M, Akimoto A, James MH, Jones P. Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. Int J Chron Obstruct Pulmon Dis. 2018;13:3459–3471. doi:10.2147/COPD.S165187
  • Makita H, Suzuki M, Konno S, et al. Unique mortality profile in Japanese patients with COPD: an analysis from the hokkaido COPD Cohort Study. Int J Chron Obstruct Pulmon Dis. 2020;15:2081–2090. doi:10.2147/COPD.S264437
  • Shibata Y, Inoue S, Igarashi A, et al. A lower level of forced expiratory volume in 1 second is a risk factor for all-cause and cardiovascular mortality in a Japanese population: the Takahata study. PLoS One. 2013;8(12):e83725. doi:10.1371/journal.pone.0083725
  • Shibata Y, Inoue S, Watanabe M. Impact of reduced pulmonary function in the Japanese general population: lessons from the Yamagata-Takahata study. Respir Investig. 2019;57(3):220–226. doi:10.1016/j.resinv.2019.01.005
  • Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. Eur Respir J. 2012;39(5):1230–1240. doi:10.1183/09031936.00126011
  • Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J. 2011;20(1):15–22.
  • Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. doi:10.1371/journal.pone.0152618
  • Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
  • Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the nippon COPD Epidemiology study. Respirology. 2004;9(4):458–465. doi:10.1111/j.1440-1843.2004.00637.x
  • Omori H, Kaise T, Suzuki T, Hagan G. Prevalence of airflow limitation in subjects undergoing comprehensive health examination in Japan: survey of chronic obstructive pulmonary disease patients epidemiology in Japan. Int J Chron Obstruct Pulmon Dis. 2016;11:873–880. doi:10.2147/COPD.S99935
  • Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750. doi:10.1016/S0140-6736(07)61377-4
  • Kaplan A, Thomas M. Screening for COPD: the gap between logic and evidence. Eur Respir Rev. 2017;26(143):143. doi:10.1183/16000617.0113-2016
  • Ruppel GL, Carlin BW, Hart M, Doherty DE. Office spirometry in primary care for the diagnosis and management of COPD: national lung health education program update. Respir Care. 2018;63(2):242–252. doi:10.4187/respcare.05710
  • Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J. 2020;55(1):1901217. doi:10.1183/13993003.01217-2019
  • Wan ES, Fortis S, Regan EA, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study. Am J Respir Crit Care Med. 2018;198(11):1397–1405. doi:10.1164/rccm.201804-0663OC
  • Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res. 2014;15(1):89. doi:10.1186/s12931-014-0089-y
  • Adibi A, Sadatsafavi M. Looking at the COPD spectrum through “PRISm”. Eur Respir J. 2020;55(1):1. doi:10.1183/13993003.02217-2019
  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2020. Available from: https://goldcopd.org/gold-reports/. Accessed September 10, 2020.
  • Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
  • Couper D, LaVange LM, Han M, et al. Design of the subpopulations and intermediate outcomes in COPD Study (SPIROMICS): table 1. Thorax. 2014;69(5):491–494. doi:10.1136/thoraxjnl-2013-203897
  • Strand M, Austin E, Moll M, et al. A risk prediction model for mortality among smokers in the COPDGene® Study. Chronic Obstr Pulm Dis. 2020;7(4):346–361. doi:10.15326/jcopdf.7.4.2020.0146
  • Martinez FJ, Mannino D, Leidy NK, et al. A new approach for identifying patients with undiagnosed chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(6):748–756. doi:10.1164/rccm.201603-0622OC
  • Samukawa T, Matsumoto K, Tsukuya G, et al. Development of a self-scored persistent airflow obstruction screening questionnaire in a general Japanese population: the Hisayama study. Int J Chron Obstruct Pulmon Dis. 2017;12:1469–1481. doi:10.2147/COPD.S130453
  • Schalet BD, Hays RD, Jensen SE, Beaumont JL, Fries JF, Cella D. Validity of PROMIS physical function measured in diverse clinical samples. J Clin Epidemiol. 2016;73:112–118. doi:10.1016/j.jclinepi.2015.08.039
  • Reddel HK, Gerhardsson de Verdier M, Agustí A, et al. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res. 2019;5(1):1. doi:10.1183/23120541.00036-2018
  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD. 2020. Available from: https://goldcopd.org/gold-reports/. Accessed May 21, 2021.
  • Tsuda T, Suematsu R, Kamohara K, et al. Development of the Japanese version of the COPD assessment test. Respir Investig. 2012;50(2):34–39. doi:10.1016/j.resinv.2012.05.003
  • Cella D, Choi SW, Condon DM, et al. PROMIS(®) adult health profiles: efficient short-form measures of seven health domains. Value Health. 2019;22(5):537–544. doi:10.1016/j.jval.2019.02.004
  • Han MK, Agusti A, Celli BR, et al. From GOLD 0 to pre-COPD. Am J Respir Crit Care Med. 2021;203(4):414–423. doi:10.1164/rccm.202008-3328PP
  • Siafakas N, Bizymi N, Mathioudakis A, Corlateanu A. EARLY versus MILD Chronic Obstructive Pulmonary Disease (COPD). Respir Med. 2018;140:127–131. doi:10.1016/j.rmed.2018.06.007
  • Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374(19):1811–1821. doi:10.1056/NEJMoa1505971
  • Miyazaki M, Nakamura H, Chubachi S, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res. 2014;15(1):13. doi:10.1186/1465-9921-15-13
  • Suzuki M, Makita H, Ito YM, Nagai K, Konno S, Nishimura M. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J. 2014;43(5):1289–1297. doi:10.1183/09031936.00110213
  • Kotz D, Nelemans P, van Schayck CP, Wesseling GJ. External validation of a COPD diagnostic questionnaire. Eur Respir J. 2008;31(2):298–303. doi:10.1183/09031936.00074307
  • Marcos PJ, de Molina RM, Casamor R. Risk stratification for COPD diagnosis through an active search strategy in primary care. Int J Chron Obstruct Pulmon Dis. 2016;11:431. doi:10.2147/COPD.S98659
  • Weiss G, Steinacher I, Lamprecht B, et al. Development and validation of the Salzburg COPD-screening questionnaire (SCSQ): a questionnaire development and validation study. NPJ Prim Care Respir Med. 2017;27(1):4. doi:10.1038/s41533-016-0005-7
  • Make BJ. COPD: a new diagnostic paradigm. Chronic Obstr Pulm Dis. 2019;6(5):438–443. doi:10.15326/jcopdf.6.5.2019.0172
  • Bhatta L, Leivseth L, Carslake D, et al. Comparison of pre- and post-bronchodilator lung function as predictors of mortality: the HUNT Study. Respirology. 2020;25(4):401–409. doi:10.1111/resp.13648
  • Mannino DM, Diaz-Guzman E, Buist S. Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respir Res. 2011;12(1):136. doi:10.1186/1465-9921-12-136
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
  • Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44(4):873–884. doi:10.1183/09031936.00025214